Steven M Paul - Net Worth and Insider Trading

Steven M Paul Net Worth

The estimated net worth of Steven M Paul is at least $168 Million dollars as of 2024-04-20. Steven M Paul is the Director of Bright Horizons Family Solutions Inc and owns about 763,650 shares of Bright Horizons Family Solutions Inc (BFAM) stock worth over $80 Million. Steven M Paul is the EVP, Science and Technology of Eli Lilly and Co and owns about 50,300 shares of Eli Lilly and Co (LLY) stock worth over $37 Million. Steven M Paul is also the PRESIDENT & CEO of Karuna Therapeutics Inc and owns about 108,849 shares of Karuna Therapeutics Inc (KRTX) stock worth over $36 Million. Besides these, Steven M Paul also holds Sage Therapeutics Inc (SAGE) , Voyager Therapeutics Inc (VYGR) , Alnylam Pharmaceuticals Inc (ALNY) . Details can be seen in Steven M Paul's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Steven M Paul has not made any transactions after 2021-08-18 and currently still holds the listed stock(s).

Transaction Summary of Steven M Paul

To

Steven M Paul Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Steven M Paul owns 5 companies in total, including Alnylam Pharmaceuticals Inc () , Karuna Therapeutics Inc () , and Sage Therapeutics Inc () among others .

Click here to see the complete history of Steven M Paul’s form 4 insider trades.

Insider Ownership Summary of Steven M Paul

Ticker Comapny Transaction Date Type of Owner
Alnylam Pharmaceuticals Inc 2020-12-18 director
Karuna Therapeutics Inc 2021-08-18 director & President & CEO
Sage Therapeutics Inc 2019-03-21 director
Voyager Therapeutics Inc 2016-01-14 director & President and CEO
Eli Lilly and Co 2008-02-04 EVP & Science and Technology

Steven M Paul Latest Holdings Summary

Steven M Paul currently owns a total of 6 stocks. Among these stocks, Steven M Paul owns 763,650 shares of Bright Horizons Family Solutions Inc (BFAM) as of May 1, 2015, with a value of $80 Million and a weighting of 47.62%. Steven M Paul owns 50,300 shares of Eli Lilly and Co (LLY) as of February 4, 2008, with a value of $37 Million and a weighting of 21.81%. Steven M Paul also owns 108,849 shares of Karuna Therapeutics Inc (KRTX) as of August 18, 2021, with a value of $36 Million and a weighting of 21.43%. The other 3 stocks Sage Therapeutics Inc (SAGE) , Voyager Therapeutics Inc (VYGR) , Alnylam Pharmaceuticals Inc (ALNY) have a combined weighting of 9.14% among all his current holdings.

Latest Holdings of Steven M Paul

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BFAM Bright Horizons Family Solutions Inc 2015-05-01 763,650 104.45 79,763,243
LLY Eli Lilly and Co 2008-02-04 50,300 726.31 36,533,393
KRTX Karuna Therapeutics Inc 2021-08-18 108,849 329.83 35,901,666
SAGE Sage Therapeutics Inc 2019-03-21 646,830 13.34 8,628,712
VYGR Voyager Therapeutics Inc 2016-01-14 872,351 7.50 6,542,633
ALNY Alnylam Pharmaceuticals Inc 2020-12-18 1,000 144.39 144,390

Holding Weightings of Steven M Paul


Steven M Paul Form 4 Trading Tracker

According to the SEC Form 4 filings, Steven M Paul has made a total of 0 transactions in Bright Horizons Family Solutions Inc (BFAM) over the past 5 years. The most-recent trade in Bright Horizons Family Solutions Inc is the sale of 20,000 shares on May 1, 2015, which brought Steven M Paul around $1 Million.

According to the SEC Form 4 filings, Steven M Paul has made a total of 0 transactions in Eli Lilly and Co (LLY) over the past 5 years. The most-recent trade in Eli Lilly and Co is the sale of 19,822 shares on February 4, 2008, which brought Steven M Paul around $1 Million.

According to the SEC Form 4 filings, Steven M Paul has made a total of 3 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Karuna Therapeutics Inc is the acquisition of 2,364 shares on August 18, 2021, which cost Steven M Paul around $250,253.

More details on Steven M Paul's insider transactions can be found in the Insider Trading History of Steven M Paul table.

Insider Trading History of Steven M Paul

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Steven M Paul Trading Performance

GuruFocus tracks the stock performance after each of Steven M Paul's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Steven M Paul is -0.42%. GuruFocus also compares Steven M Paul's trading performance to market benchmark return within the same time period. The performance of stocks bought by Steven M Paul within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Steven M Paul's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Steven M Paul

Average Return

193.27%

Average return per transaction

Outperforming Transactions

67%

2 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.79 -0.42 89.87 193.27 63.67 33.97
Relative Return to S&P 500(%) -5 -5.74 82.68 187.27 50.06 24.25

Steven M Paul Ownership Network

Ownership Network List of Steven M Paul

No Data

Ownership Network Relation of Steven M Paul


Steven M Paul Owned Company Details

What does Alnylam Pharmaceuticals Inc do?

Who are the key executives at Alnylam Pharmaceuticals Inc?

Steven M Paul is the director of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include EVP & Chief Commercial Officer Tolga Tanguler , CMO & EVP Dev & Med Affairs Pushkal Garg , and EVP & CLO & Secretary Indrani Lall Franchini .

Alnylam Pharmaceuticals Inc () Insider Trades Summary

Over the past 18 months, Steven M Paul made no insider transaction in Alnylam Pharmaceuticals Inc (). Other recent insider transactions involving Alnylam Pharmaceuticals Inc () include a net sale of 30,567 shares made by Pushkal Garg , a net sale of 7,095 shares made by Indrani Lall Franchini , and a net sale of 14,604 shares made by Yvonne Greenstreet .

In summary, during the past 3 months, insiders sold 36,501 shares of Alnylam Pharmaceuticals Inc () in total and bought 0 shares, with a net sale of 36,501 shares. During the past 18 months, 159,676 shares of Alnylam Pharmaceuticals Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 159,676 shares.

Alnylam Pharmaceuticals Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Alnylam Pharmaceuticals Inc Insider Transactions

No Available Data

Steven M Paul Mailing Address

Above is the net worth, insider trading, and ownership report for Steven M Paul. You might contact Steven M Paul via mailing address: C/o Eli Litty & Co, Liiy Corporate Center Dc 1093, Indianapolis In 46285.

Discussions on Steven M Paul

No discussions yet.